NCT00576251View on ClinicalTrials.gov

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

PHASE3CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

March 31, 2008

Conditions
Ocular Inflammation Associated With Blepharaconjunctivitis
Interventions
DRUG

Tobramycin 0.3%/Dexamethasone 0.05%

Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days

DRUG

TOBRADEX

TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days

Trial Locations (1)

77090

Houston, Houston

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY